Skip to content
Pharma Observatory a Scientist.com platform
  • Trial site

Trial site location from the registry's own city and country. GeoNames (geonames.org).

Clinical trial site

Seoul National University Hospital

Seoul National University Hospital in Seoul, South Korea is listed as a site for 2,669 registered clinical trials, 651 of them ongoing.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Registered trials 2,669
Ongoing 651

This page covers the site record Seoul National University Hospital in Seoul, South Korea: the trials that list it by this name in ClinicalTrials.gov. The same place can be registered under other names, each with its own page and its own trials, and a count here is a number of registered trials, not of patients enrolled. The organization of the same name, Seoul National University Hospital, also sponsors trials.

Get the Seoul National University Hospital report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Trials by phase

Registered trials that list this site, by trial phase. 2,669 trials counted.

  • Phase 1 353 trials
  • Phase 1/2 166 trials
  • Phase 2 377 trials
  • Phase 2/3 41 trials
  • Phase 3 662 trials
  • Phase 4 183 trials
  • Not applicable 510 trials
  • Observational 377 trials

Trials by status

The registry's own status summary: Ongoing, Completed, Terminated or Other.

  • Ongoing 651 trials
  • Completed 1,356 trials
  • Terminated 235 trials
  • Other 427 trials

Trials over time

Trials registered with a start date in each year, 1990 onward, most recent years first.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 213

1997: 2 trials (Observational 2) 2000: 1 trials (Observational 1) 2001: 3 trials (Observational 1, Phase 3 2) 2002: 2 trials (Phase 3 2) 2003: 1 trials (Phase 3 1) 2004: 12 trials (Observational 2, Not applicable 1, Phase 4 3, Phase 2 6) 2005: 11 trials (Not applicable 1, Phase 4 4, Phase 3 5, Phase 2 1) 2006: 23 trials (Observational 2, Phase 4 7, Phase 3 5, Phase 2 6, Phase 1 3) 2007: 29 trials (Observational 9, Not applicable 1, Phase 4 1, Phase 3 9, Phase 2 3, Phase 1/2 3, Phase 1 3) 2008: 49 trials (Observational 4, Not applicable 7, Phase 4 10, Phase 3 6, Phase 2/3 1, Phase 2 15, Phase 1/2 3, Phase 1 3) 2009: 59 trials (Observational 12, Not applicable 6, Phase 4 9, Phase 3 10, Phase 2 9, Phase 1/2 3, Phase 1 10) 2010: 74 trials (Observational 11, Not applicable 8, Phase 4 17, Phase 3 13, Phase 2/3 1, Phase 2 12, Phase 1/2 3, Phase 1 9) 2011: 100 trials (Observational 23, Not applicable 19, Phase 4 14, Phase 3 15, Phase 2/3 4, Phase 2 14, Phase 1 11) 2012: 93 trials (Observational 17, Not applicable 12, Phase 4 14, Phase 3 27, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 10) 2013: 119 trials (Observational 15, Not applicable 40, Phase 4 6, Phase 3 30, Phase 2/3 2, Phase 2 13, Phase 1/2 2, Phase 1 11) 2014: 116 trials (Observational 15, Not applicable 33, Phase 4 10, Phase 3 28, Phase 2 11, Phase 1/2 7, Phase 1 12) 2015: 126 trials (Observational 22, Not applicable 29, Phase 4 7, Phase 3 28, Phase 2/3 1, Phase 2 20, Phase 1/2 3, Phase 1 16) 2016: 165 trials (Observational 28, Not applicable 38, Phase 4 14, Phase 3 37, Phase 2 18, Phase 1/2 7, Phase 1 23) 2017: 184 trials (Observational 27, Not applicable 44, Phase 4 12, Phase 3 47, Phase 2/3 2, Phase 2 22, Phase 1/2 10, Phase 1 20) 2018: 190 trials (Observational 25, Not applicable 49, Phase 4 4, Phase 3 42, Phase 2/3 5, Phase 2 25, Phase 1/2 13, Phase 1 27) 2019: 178 trials (Observational 31, Not applicable 36, Phase 4 12, Phase 3 37, Phase 2/3 4, Phase 2 23, Phase 1/2 17, Phase 1 18) 2020: 196 trials (Observational 17, Not applicable 41, Phase 4 7, Phase 3 41, Phase 2/3 4, Phase 2 32, Phase 1/2 14, Phase 1 40) 2021: 213 trials (Observational 30, Not applicable 46, Phase 4 6, Phase 3 53, Phase 2/3 1, Phase 2 35, Phase 1/2 19, Phase 1 23) 2022: 199 trials (Observational 34, Not applicable 33, Phase 4 3, Phase 3 48, Phase 2/3 4, Phase 2 27, Phase 1/2 20, Phase 1 30) 2023: 157 trials (Observational 16, Not applicable 28, Phase 4 8, Phase 3 47, Phase 2/3 1, Phase 2 16, Phase 1/2 13, Phase 1 28) 2024: 158 trials (Observational 15, Not applicable 16, Phase 4 4, Phase 3 49, Phase 2/3 4, Phase 2 25, Phase 1/2 13, Phase 1 32) 2025: 119 trials (Observational 15, Not applicable 11, Phase 4 4, Phase 3 48, Phase 2/3 3, Phase 2 17, Phase 1/2 10, Phase 1 11)

Trials that list this site and are registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 86
2025 119
2024 158
2023 157
2022 199
2021 213
2020 196
2019 178
2018 190
2017 184

2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here

Recent trials

The newest registered trials that list this site. Each title opens its ClinicalTrials.gov record.

Source: ClinicalTrials.gov

Lead sponsors

Most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Conditions studied

The specific conditions of the trials that list this site, most trials first.